This paper was prepared by the 2003-2005 ACCP Research Affairs Committee: Susan Fagan, Pharm.D., FCCP, BCPS, Co-chair; Kevin M. Sowinski, Pharm.D., FCCP, BCPS, Co-chair; Robert Blouin, Pharm.D., FCCP; Daniel Canafax, Pharm.D., FCCP; Annie Kai I. Cheang, Pharm.D., BCPS; M. Lynn Crismon, Pharm.D., FCCP, BCPP; Peter Djuric, Pharm.D.; Lisa Dolovich, Pharm.D., M.S.; Anita Groves, Pharm.D., M.S.; Collin Hovinga, Pharm.D.; Daren Knoell, Pharm.D., FCCP; David Knoppert, M.Sc.(Pharm.), FCCP, M.Sc.; Jill Kolesar, Pharm.D., FCCP, BCPS; Yi Min (Julie) Ku, Pharm.D.; Kari Olson, Pharm.D., BCPS; J. Jason Sims, Pharm.D.; Judith A. Smith, Pharm.D., FCCP, BCOP; Daniel Touchette, Pharm.D., M.A.; and Michael Ujhelyi, Pharm.D., FCCP. Approved by the ACCP Board of Regents on April 8, 2005.
Address reprint requests to the American College of Clinical Pharmacy, 3101 Broadway, Suite 650, Kansas City, MO 64111; e-mail: [email protected]; or download from http://www.accp.com.
